4,022 Shares in Encompass Health Co. (NYSE:EHC) Purchased by Foundry Partners LLC

Foundry Partners LLC acquired a new stake in shares of Encompass Health Co. (NYSE:EHC) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 4,022 shares of the company’s stock, valued at approximately $345,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in shares of Encompass Health by 1.7% in the first quarter. Vanguard Group Inc. now owns 10,166,147 shares of the company’s stock worth $839,520,000 after buying an additional 169,113 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Encompass Health by 5.8% in the 4th quarter. Wellington Management Group LLP now owns 8,215,770 shares of the company’s stock worth $548,156,000 after purchasing an additional 449,230 shares during the last quarter. TD Asset Management Inc raised its stake in shares of Encompass Health by 16.0% in the 1st quarter. TD Asset Management Inc now owns 2,283,674 shares of the company’s stock valued at $188,586,000 after purchasing an additional 314,488 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its position in shares of Encompass Health by 6.7% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 1,928,449 shares of the company’s stock worth $128,666,000 after purchasing an additional 120,527 shares during the last quarter. Finally, Brown Advisory Inc. increased its holdings in Encompass Health by 6.2% in the fourth quarter. Brown Advisory Inc. now owns 1,791,517 shares of the company’s stock valued at $119,530,000 after buying an additional 104,847 shares during the last quarter. 97.25% of the stock is currently owned by hedge funds and other institutional investors.

Encompass Health Trading Down 1.9 %

Encompass Health stock opened at $91.66 on Friday. Encompass Health Co. has a 52-week low of $57.55 and a 52-week high of $94.38. The company has a quick ratio of 1.35, a current ratio of 1.35 and a debt-to-equity ratio of 1.08. The firm has a market capitalization of $9.23 billion, a price-to-earnings ratio of 24.77, a PEG ratio of 1.42 and a beta of 0.88. The firm has a 50-day moving average price of $88.66 and a two-hundred day moving average price of $84.10.

Encompass Health (NYSE:EHC) last issued its quarterly earnings data on Monday, August 5th. The company reported $1.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.10. Encompass Health had a return on equity of 17.83% and a net margin of 7.88%. The business had revenue of $1.30 billion during the quarter, compared to the consensus estimate of $1.30 billion. During the same period in the previous year, the firm posted $0.95 earnings per share. The business’s revenue was up 9.6% on a year-over-year basis. Sell-side analysts expect that Encompass Health Co. will post 4.17 earnings per share for the current year.

Encompass Health Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Stockholders of record on Tuesday, October 1st will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.74%. This is a positive change from Encompass Health’s previous quarterly dividend of $0.15. The ex-dividend date of this dividend is Tuesday, October 1st. Encompass Health’s dividend payout ratio (DPR) is 18.38%.

Wall Street Analyst Weigh In

EHC has been the topic of a number of research analyst reports. Truist Financial increased their target price on Encompass Health from $100.00 to $104.00 and gave the stock a “buy” rating in a report on Thursday, August 15th. UBS Group lifted their price objective on shares of Encompass Health from $96.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Barclays dropped their target price on shares of Encompass Health from $113.00 to $109.00 and set an “overweight” rating on the stock in a report on Tuesday, August 6th. Leerink Partnrs raised shares of Encompass Health to a “strong-buy” rating in a report on Wednesday, July 10th. Finally, Royal Bank of Canada raised their target price on shares of Encompass Health from $83.00 to $95.00 and gave the stock an “outperform” rating in a report on Wednesday, May 22nd. Nine investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $100.38.

Insider Activity at Encompass Health

In related news, CFO Douglas E. Coltharp sold 12,260 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $86.34, for a total value of $1,058,528.40. Following the completion of the transaction, the chief financial officer now owns 136,227 shares in the company, valued at approximately $11,761,839.18. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.10% of the company’s stock.

About Encompass Health

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.